Skip to main content

Advertisement

Log in

Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor

  • Cell Line
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Tenosynovial giant cell tumor (TGCT) is a mesenchymal tumor arising from the synovium of tendon sheath and joints, characterized by translocation t(1;2)(p13;q37). Clinical behaviors of TGCT range from favorable to locally aggressive and further research is required to lead the identification of novel therapeutic avenues for TGCT. Patient-derived cell lines are an indispensable tool for interrogating molecular mechanisms underlying the progression of disease. However, only one TGCT cell line is currently available from cell banks, and a paucity of adequate patient-derived cells hinders basic and translational research. This study aimed to establish a novel cell line of TGCT. To this end, a novel cell line, NCC-TGCT1-C1 was established from the primary tumor tissue of a 40-year-old female patient with TGCT. The cells exhibited translocation t(1;2)(p13;q37), generating COL6A3-CSF1 fusion gene. The cells were maintained as a monolayer culture through more than 30 passages over 12 months. The cells exhibited continuous growth and the ability for spheroid formation and invasion. When used in a high-throughput assay to evaluate the anti-proliferative effects of 164 anticancer drugs, the cells responded strongly to a kinase inhibitor such as gefitinib, and mitoxantrone. Our results indicate that the novel TGCT cell line, designated NCC-TGCT1-C1, was successfully established and could be used to study TGCT development and the effects of anticancer agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Mastboom MJL, Verspoor FGM, Verschoor AJ, et al. Higher incidence rates than previously known in tenosynovial giant cell tumors. Acta Orthop. 2017;88:688–94.

    Article  Google Scholar 

  2. Ravi V, Wang WL, Lewis VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol. 2011;23:361–6.

    Article  CAS  Google Scholar 

  3. Savage RC, Mustafa EB. Giant cell tumor of tendon sheath (localized nodular tenosynovitis). Ann Plast Surg. 1984;13:205–10.

    Article  CAS  Google Scholar 

  4. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. Soft Tissue and Bone Tumours. Geneva: WHO Press; 2020.

    Google Scholar 

  5. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006;103:690–5.

    Article  CAS  Google Scholar 

  6. Temple HT. Pigmented villonodular synovitis therapy with MSCF-1 inhibitors. Curr Opin Oncol. 2012;24:404–8.

    Article  CAS  Google Scholar 

  7. Möller E, Mandahl N, Mertens F, Panagopoulos I. Molecular identification of COL6A3-CSF1 fusion transcripts in tenosynovial giant cell tumors. Genes Chromosomes Cancer. 2008;47:21–5.

    Article  Google Scholar 

  8. Reilly KE, Stern PJ, Dale JA. Recurrent giant cell tumors of the tendon sheath. J Hand Surg. 1999;24:1298–302.

    Article  CAS  Google Scholar 

  9. Gelderblom H, Cropet C, Chevreau C, et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2018;19:639–48.

    Article  CAS  Google Scholar 

  10. Cassier PA, Gelderblom H, Stacchiotti S, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012;118:1649–55.

    Article  CAS  Google Scholar 

  11. Cassier PA, Italiano A, Gomez-Roca CA, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015;16:949–56.

    Article  CAS  Google Scholar 

  12. Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394:478–87.

    Article  CAS  Google Scholar 

  13. Sharma SV, Haber DA, Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010;10:241–53.

    Article  CAS  Google Scholar 

  14. Barretina J, Caponigro G, Stransky N, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.

    Article  CAS  Google Scholar 

  15. Iorio F, Knijnenburg TA, Vis DJ, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166:740–54.

    Article  CAS  Google Scholar 

  16. Teicher BA, Polley E, Kunkel M, et al. Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression. Mol Cancer Ther. 2015;14:2452–62.

    Article  CAS  Google Scholar 

  17. Bairoch A. The cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29:25–38.

    Article  Google Scholar 

  18. Yoshimatsu Y, Noguchi R, Tsuchiya R, et al. Establishment and characterization of NCC-CDS2-C1: a novel patient-derived cell line of CIC-DUX4 sarcoma. Hum Cell. 2020;33:427–36.

    Article  Google Scholar 

  19. Capes-Davis A, Reid YA, Kline MC, et al. Match criteria for human cell line authentication: where do we draw the line? Int J Cancer. 2013;132:2510–9.

    Article  CAS  Google Scholar 

  20. Nath S, Devi GR. Three-dimensional culture systems in cancer research: focus on tumor spheroid model. Pharmacol Ther. 2016;163:94–108.

    Article  CAS  Google Scholar 

  21. Voissiere A, Jouberton E, Maubert E, et al. Development and characterization of a human three-dimensional chondrosarcoma culture for in vitro drug testing. PLoS ONE. 2017;12:e0181340.

    Article  Google Scholar 

  22. Herbst RS, Fukuoka M, Baselga J. Gefitinib—a novel targeted approach to treating cancer. Nat Rev Cancer. 2004;4:956–65.

    Article  CAS  Google Scholar 

  23. Faulds D, Balfour JA, Chrisp P, Langtry HD. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 1991; 41:400–49.

Download references

Acknowledgements

We appreciate the technical support of Miss Yu Kuwata (Division of Rare Cancer Research, National Cancer Center). We would like to thank the Tochigi Cancer Center Operating Room Nurse Team and the Secretary of the Medical Office for their assistance in processing and transporting the samples. We would like to thank Editage (https://www.editage.jp) for English-language editing and for their constructive comments on the manuscript.

Funding

This research was supported by Japan Agency for Medical Research and Development (grant number 20ck0106537h0001).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tadashi Kondo.

Ethics declarations

Conflict of interest

The authors have no conflict of interest in this study.

Ethics approval

This study was approved by the ethics committee of the Tochigi Cancer Center, and the National Cancer Center.

Consent to publish

Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Noguchi, R., Yoshimatsu, Y., Ono, T. et al. Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor. Human Cell 34, 254–259 (2021). https://doi.org/10.1007/s13577-020-00425-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-020-00425-8

Keywords

Navigation